These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease. Vavlukis M; Kedev S Curr Pharm Des; 2018; 24(4):427-441. PubMed ID: 29283060 [TBL] [Abstract][Full Text] [Related]
23. Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients With Type 2 Diabetes: A Cohort Study. Al-Salameh A; Bucher S; Bauduceau B; Benattar-Zibi L; Berrut G; Bertin P; Corruble E; Danchin N; Derumeaux G; Doucet J; Falissard B; Forette F; Hanon O; Ourabah R; Pasquier F; Pinget M; Ringa V; Becquemont L Can J Diabetes; 2018 Aug; 42(4):365-371.e2. PubMed ID: 29037572 [TBL] [Abstract][Full Text] [Related]
24. Management of Lipid Abnormalities in Patients with Diabetes. Sillars A; Sattar N Curr Cardiol Rep; 2019 Nov; 21(11):147. PubMed ID: 31758270 [TBL] [Abstract][Full Text] [Related]
25. The significance of plasma adrenomedullin and calcitonin gene-related peptide concentration in patients with Type 2 diabetes mellitus who are treated for cardiovascular risk factors. Charvat J; Svab P; Havlin J; Bilek R; Zamrazil V Neuro Endocrinol Lett; 2014; 35(2):154-8. PubMed ID: 24878981 [TBL] [Abstract][Full Text] [Related]
27. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction. Basile J; Houston M; Ferrario CM J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795 [No Abstract] [Full Text] [Related]
28. [How to create cooperative patient for antihypertensive and hypolipidemic therapy]. Piťha J Vnitr Lek; 2017; 63(4):272-276. PubMed ID: 28520451 [TBL] [Abstract][Full Text] [Related]
29. [Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. Kékes E Orv Hetil; 2008 Sep; 149(39):1827-37. PubMed ID: 18805771 [TBL] [Abstract][Full Text] [Related]
30. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
31. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders. Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821 [No Abstract] [Full Text] [Related]
32. [Part II. Combination statin plus fibrate regimens (free and fixed)]. Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():11-9. PubMed ID: 27473466 [No Abstract] [Full Text] [Related]
33. The gap between the current dyslipidemia guidelines and the physicians' treatment targets in patients with type 2 diabetes in Turkey. Kahya Eren N; Harman E; Dolek D; Emren S; Tütüncüoğlu AP; Nazli C; Ergene O Minerva Cardioangiol; 2014 Jun; 62(3):287-95. PubMed ID: 24831765 [TBL] [Abstract][Full Text] [Related]
35. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study]. Båvenholm P; Attvall S; Nilsson PM Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161 [No Abstract] [Full Text] [Related]
36. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. Campbell J; Mohiuddin SM Drugs Today (Barc); 2010 Oct; 46(10):757-64. PubMed ID: 21076712 [TBL] [Abstract][Full Text] [Related]
37. Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians. Tomasik T; Windak A; Seifert B; Kersnik J; Kijowska V; Dubas K J Cardiovasc Pharmacol Ther; 2013 May; 18(3):234-42. PubMed ID: 23277158 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164 [TBL] [Abstract][Full Text] [Related]
39. Combination lipid therapy in type 2 diabetes mellitus. Vergès B Expert Opin Pharmacother; 2011 Jun; 12(9):1393-403. PubMed ID: 21323502 [TBL] [Abstract][Full Text] [Related]
40. The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients. Howes LG Diabetes Obes Metab; 2006 Jan; 8(1):8-14. PubMed ID: 16367877 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]